Loss of Yasmin contraceptive patent knocks Bayer
FRANKFURT (Reuters) - Shares in Bayer slumped as much as 5.6 percent on Tuesday after a U.S. court voided the patent on its Yasmin oral contraceptive drug, prompting the German group to tweak its healthcare margin goal.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=A20tep" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=A20tep)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=NtK8EqF" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=NtK8EqF) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=ROt1sXf" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=ROt1sXf) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=BD5DhLf" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=BD5DhLf)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/245391962" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/245391962/idUSL0489366820080304